| Literature DB >> 34329471 |
Ying Liang1, Qi Lu2, Wei Li1, Dapeng Zhang3, Fanglin Zhang4, Qingping Zou1, Lu Chen1, Ying Tong1, Mengxing Liu1, Shaoxuan Wang1, Wenxuan Li1, Xiaoguang Ren1, Peng Xu1, Zhicong Yang1, Shihua Dong1, Baolong Zhang1, Yanni Huang4, Daqiang Li4, Hailin Wang3, Wenqiang Yu1.
Abstract
Dysfunction of Tumour Suppressor Genes (TSGs) is a common feature in carcinogenesis. Epigenetic abnormalities including DNA hypermethylation or aberrant histone modifications in promoter regions have been described for interpreting TSG inactivation. However, in many instances, how TSGs are silenced in tumours are largely unknown. Given that miRNA with low expression in tumours is another recognized signature, we hypothesize that low expression of miRNA may reduce the activity of TSG related enhancers and further lead to inactivation of TSG during cancer development. Here, we reported that low expression of miRNA in cancer as a recognized signature leads to loss of function of TSGs in breast cancer. In 157 paired breast cancer and adjacent normal samples, tumour suppressor gene GPER1 and miR-339 are both downregulated in Luminal A/B and Triple Negative Breast Cancer subtypes. Mechanistic investigations revealed that miR-339 upregulates GPER1 expression in breast cancer cells by switching on the GPER1 enhancer, which can be blocked by enhancer deletion through the CRISPR/Cas9 system. Collectively, our findings reveal novel mechanistic insights into TSG dysfunction in cancer development, and provide evidence that reactivation of TSG by enhancer switching may be a promising alternative strategy for clinical breast cancer treatment.Entities:
Year: 2021 PMID: 34329471 DOI: 10.1093/nar/gkab626
Source DB: PubMed Journal: Nucleic Acids Res ISSN: 0305-1048 Impact factor: 16.971